Zobrazeno 1 - 10
of 665
pro vyhledávání: '"Douglas A. Ross"'
Autor:
Alexander Belyaev, Aldo Deandrea, Stefano Moretti, Luca Panizzi, Douglas A. Ross, Nakorn Thongyoi
Publikováno v:
Frontiers in Physics, Vol 12 (2024)
We introduce a new class of renormalizable models for dark matter with a minimal particle content, consisting of a dark SU(2)D gauge sector connected to the standard model through a vector-like fermion mediator, not requiring a Higgs portal, in which
Externí odkaz:
https://doaj.org/article/4269b92ad2f94eb0b6c490737d2eead5
Autor:
Douglas A. Ross, Agustín Sabio Vera
Publikováno v:
Physics Letters B, Vol 760, Iss C, Pp 428-431 (2016)
We investigate the sensitivity of the discrete BFKL spectrum, which appears in the gluon Green function when the running coupling is considered, to a lower cut-off in the relative rapidities of the emitted particles. We find that the eigenvalues asso
Externí odkaz:
https://doaj.org/article/ce1a7412cc974436baffe2ee05b0cb3b
Autor:
Andrew B. Thompson B.S., Douglas A. Ross M.D. F.A.C.S., Paul Berard M.D., Jaszmin Figueroa-Bodine M.D., Nancy Livada P.A.-C., Sara L. Richer M.D. F.A.C.S.
Publikováno v:
Allergy & Rhinology, Vol 5 (2014)
Hereditary hemorrhagic telangiectasia (HHT) is a disease characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations. The genetic mutations that cause this disease result in elevated levels of vascular endothelial growth f
Externí odkaz:
https://doaj.org/article/8eeb84555286493dbe02ea106676b8d4
Autor:
Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurélie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jérôme Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini
Publikováno v:
Clinical Cancer Research. :OF1-OF8
Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal can
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4332a88187297585a34006d3116e37fa
https://doi.org/10.1158/1078-0432.22692642
https://doi.org/10.1158/1078-0432.22692642
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Purpose:AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c77aca2057d946a319565137c40acb
https://doi.org/10.1158/1078-0432.c.6615933.v1
https://doi.org/10.1158/1078-0432.c.6615933.v1
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50452b50c4a7164dbe128538020db82a
https://doi.org/10.1158/1078-0432.22692633
https://doi.org/10.1158/1078-0432.22692633
Autor:
Vikas Mehta, Ankita Naraparaju, David Liao, Louise Davies, Bryan R. Haugen, Peter A. Kopp, Susan J. Mandel, Yuri E. Nikiforov, Douglas S. Ross, Jennifer J. Shin, R. Michael Tuttle, Gregory W. Randolph
Publikováno v:
Thyroid
BACKGROUND: The noninvasive subtype of encapsulated follicular variant of papillary thyroid carcinoma (eFVPTC) has been reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in 2016 to reflect the indole
Autor:
Paul Haluska, Scott H. Kaufmann, Charles Erlichman, Marco M. Gottardis, Douglas D. Ross, Jennifer D. Tibodeau, Takeo Nakanishi, Cynthia Ten Eyck, Yan W. Asmann, Karen Flatten, Joan M. Carboni, Fei Huang, Xiaonan Hou
Supplementary Figure 1 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d25a4bed8d23420c5d7d440792c19f
https://doi.org/10.1158/1535-7163.22483487.v1
https://doi.org/10.1158/1535-7163.22483487.v1
Autor:
Paul Haluska, Scott H. Kaufmann, Charles Erlichman, Marco M. Gottardis, Douglas D. Ross, Jennifer D. Tibodeau, Takeo Nakanishi, Cynthia Ten Eyck, Yan W. Asmann, Karen Flatten, Joan M. Carboni, Fei Huang, Xiaonan Hou
Supplementary Figure 3 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f33a97bc95be6f189ea95696ab2ac63
https://doi.org/10.1158/1535-7163.22483475
https://doi.org/10.1158/1535-7163.22483475